226 results on '"Kobayashi, Roger"'
Search Results
2. An Updated Survey of SCID Outcomes Without Preconditioning Chemotherapy
3. Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies
4. PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants
5. 26 Survival and Clinical Outcomes of XLA Patients 55 years or older
6. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
7. Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study
8. Subcutaneous Immunoglobulin 16.5% (Cutaquig) in Primary Immunodeficiency Disease: Safety, Efficacy, and Patient Satisfaction with Modified Dosing Regimens
9. Subcutaneous Immunoglobulin 16.5% (Cutaquig) is Safe and Efficacious at Modified Dosing Regimens in Patients With Primary Immunodeficiency Disease
10. Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies
11. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency
12. Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies
13. Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease
14. Immune globulin therapy and kidney disease: Overview and screening, monitoring, and management recommendations
15. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency.
16. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases
17. Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
18. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm])
19. Parvovirus B19-Induced Anemia as the Presenting Manifestation of X-Linked Hyper-IgM Syndrome
20. Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome
21. Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin 16.5% Administered at Modified Dosing Regimens in Patients with Primary Immunodeficiency Diseases – Study Design
22. Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies
23. Immunoglobulin G4–related sclerosing disease of the paranasal sinus
24. Benefits of IVIG in Pediatric Acute-Onset Neuropsychiatric Syndrome (2411)
25. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]).
26. Home self-administration of intravenous immunoglobulin therapy in children
27. Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases
28. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: Use of an old method with a new product
29. Progressive Neurodegeneration in Patients with Primary Immunodeficiency Disease on IVIG Treatment
30. The home administration of IVIG in children with primary immunodeficiency
31. Early Loss of Passive Measles Antibody in Infants of Mothers with Vaccine-Induced Immunity
32. Disseminated Candidal Infections and Intravenous Hydrocortisone in Preterm Infants
33. Pediatric Adenoidal Hypertrophy and Nasal Airway Obstruction: Reduction with Aqueous Nasal Beclomethasone
34. Activation and differentiation antigens on T cells of healthy, at-risk, and HIV-infected children
35. Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study
36. Dried Blood Spots, an Affordable Tool to Collect, Ship, and Sequence gDNA from Patients with an X-Linked Agammaglobulinemia Phenotype Residing in a Developing Country
37. A Simple Method of Blood Collection to Detect Mutational Changes [BTK Gene Analysis] in Vietnamese Children With XLA [X-Linked Agammaglobulinemia]
38. Cost-effectiveness of using an extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in the US
39. What Does Screening Newborns for T-Cell Lymphopenia Find?
40. Back to the Future: 1753 - Vitamin C Remediates Scurvy, 2016 - Folinic Acid Does the Same for MTHFD1-SCID with the Help of Exome Sequencing
41. Interferon-gamma in a family with X-linked lymphoproliferative syndrome with acute Epstein-Barr virus infection
42. Cost-effectiveness of using an extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG in managing infants with cow's milk allergy in the US.
43. Pharmacokinetics of RI-002, an Investigational Igiv Preparation
44. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase
45. Immunoglobulin G4-related sclerosing disease of the paranasal sinus
46. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states
47. Long-Term Safety and Efficacy of Triamcinolone Acetonide Aqueous Nasal Spray for the Treatment of Perennial Allergic Rhinitis
48. Triamcinolone Acetonide Aqueous Nasal Inhaler for the Treatment of Spring Grass Seasonal Allergic Rhinitis in Children
49. Extended-Release Albuterol in the Treatment of 6- to 12-Year-Old Asthmatic Children
50. RISK FACTORS FOR ACUTE WHEEZING IN INFANTS AND CHILDREN: VIRUSES, PASSIVE SMOKE, AND IMMUNOGLOBULIN E (IgE) IgE ANTIBODIES TO INHALANT ALLERGENS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.